

Birkerød, 12. april 2021

**Indkaldelse til ordinær generalforsamling 2021 i
ViroGates A/S (CVR-NR. 25 73 40 33)**

Notice to convene the annual general meeting 2021 of ViroGates A/S

Der indkaldes til ordinær generalforsamling i ViroGates A/S, CVR nr. 25 73 40 33, til afholdelse som elektronisk generalforsamling.

Notice for the annual general meeting of ViroGates A/S, CVR no. 25 73 40 33, is hereby given. The meeting will be held as an electronic meeting.

tirsdag den 27. april 2021, kl. 17:00,

Tuesday, 27 April 2021, 5 PM

med følgende

with the following

Dagsorden

Agenda

1. Valg af dirigent
Election of chairman of the meeting
2. Bestyrelsens beretning om selskabets virksomhed i det forløbne år
The board's report on the company's business in the past year
3. Fremlæggelse af årsrapport med revisionspåtegning til godkendelse
Submission of the annual report with auditor's report for approval
4. Forslag fra bestyrelsen vedrørende disponering af resultatet i overensstemmelse med den godkendte årsrapport
Proposal from the board regarding the distribution of the result in accordance with the approved annual report
5. Præsentation og vejledende afstemning om vederlagsrapport
Presentation and Indicative vote on remuneration report
6. Valg af bestyrelsesmedlemmer
Election of Board of Directors
7. Honorering af bestyrelsesmedlemmer
Remuneration of Board of Directors
8. Valg af revisor
Election of auditor

9. Eventuelt

Any other business

FULDSTÆNDIGE FORSLAG

FULL PROPOSALS

Ad pkt. 1 / Re item 1

Bestyrelsen foreslår valg af advokat Nicolai Jung som dirigent.

The board proposes that attorney-at-law Nicolai Jung be elected chairman.

Ad pkt. 2 / Re item 2

Beretning afgives af bestyrelsesformanden og selskabets administrerende direktør.

The report is given by the chairman of the board and the Company's CEO.

Ad pkt. 3 / Re item 3

Bestyrelsen indstiller årsrapporten til godkendelse.

The board submits the annual report for approval.

Ad pkt. 4 / Re item 4

Bestyrelsen foreslår, at årets underskud på DKK 18.736.039 overføres til næste år ved indregning i overført resultat.

The board proposes that the year's loss of DKK 18,736,039 is transferred to the next year by application against the transferred result.

Ad pkt. 5 / Re item 5

Bestyrelsen indstiller vederlagsrapporten til en vejledende afstemning.

The board submits the remuneration report for an indicative vote.

Ad pkt. 6 / Re item 6

Alle bestyrelsesmedlemmer, Lars Kongsbak, Lars Krogsgaard, Henrik Stender og Jørgen Axel Thorball genopstiller.

It is proposed to reelect the directors, Lars Kongsbak, Lars Krogsgaard, Henrik Stender and Jørgen Axel Thorball.

Ad pkt. 7 / Re item 7

Det foreslås, at honorar for bestyrelsens arbejde i 2021 uændret fastsættes til kr. 150.000 til formanden og kr. 75.000 til hvert af de øvrige medlemmer af bestyrelsen.

It is proposed that the remuneration for the work of the board in 2021 unchanged be fixed at DKK 150,000 to the chairman and DKK 75,000 to each of the other directors.

Ad pkt. 8 / Re item 8

Bestyrelsen foreslår genvalg af BDO Statsautoriseret Revisionsaktieselskab.

The board proposes that BDO Statsautoriseret Revisionsaktieselskab be reelected.

Ad pkt. 9 / Re item 9

Der kan ikke træffes beslutninger under dette punkt.

No resolutions can be made under this item.

DK

Generalforsamlingen afholdes som et elektronisk møde uden fysisk deltagelse på grund af COVID-19 situationen.

Ret til at deltage i og stemme på generalforsamlingen tilkommer aktionærer, som er noteret i ejerbogen på registreringsdatoen eller som senest på registreringsdatoen har anmeldt og dokumenteret deres erhvervelse af aktier i Selskabet med henblik på notering i ejerbogen. Registreringsdatoen er **tirsdag den 20. april 2021**.

En aktionær eller en fuldmægtig kan deltage på generalforsamlingen med en rådgiver.

Adgangskort

Aktionærer, som ønsker at deltage i den elektroniske generalforsamling, skal anmode om et adgangskort senest fredag den 23. april 2021.

Anmodning om adgangskort til den ordinære generalforsamling kan ske:

- online via aktionærportalen på selskabets hjemmeside, <https://www.virogates.com/shareholder-portal/>,
- ved at udfylde, underskrive og fremsende tilmeldingsblanketten pr. e-mail til gf@computershare.dk eller med almindelig post til Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, eller ved at anvende tilmeldingsblanketten, som er tilgængelig på selskabets hjemmeside, <https://www.virogates.com/financial-calendar/>. Vær opmærksom på postvæsenets leveringstid, hvis tilmeldingsblanketten sendes med almindelig post, eller
- ved at kontakte Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, på telefon 4546 0997 (hverdage fra 9.00 til 15.00).

Adgangskort og oplysninger om, hvordan man deltager i den elektroniske generalforsamling, vil blive sendt til den e-mailadresse, der er angivet i aktionærportalen ved tilmeldingen.

Links til download og minimumskrav til systemer vil blive fremsendt til aktionærer, som har bestilt adgangskort.

For at kunne deltage elektronisk er hver aktionær ansvarlig for at sikre sig, at aktionæren har en mobiltelefon eller en enhed med en internetbrowser, og at aktionæren har en tilstrækkelig og fungerende internetadgang på tidspunktet for afholdelse af generalforsamlingen.

Stemmeafgivelse ved fuldmagt og brevstemmer

En aktionær kan udøve sine aktionærrettigheder ved at afgive fuldmagt *eller* brevstemme, men ikke begge dele. Afgivelse af fuldmagt eller brevstemme kan ske elektronisk via aktionærportalen på selskabets hjemmeside, <https://www.virogates.com/shareholder-portal/>. Login kræver et brugernavn og en adgangskode eller NemID. Fuldmagtstemmer og brevstemmer kan også ske ved at bruge de blanketter, der er tilgængelige på selskabets hjemmeside, <https://www.virogates.com/financial-calendar/>. Den udfyldte blanket skal sendes med almindelig post til Computershare A/S, Lottenborgvej 26 D, 1., 2800 Kgs. Lyngby, eller pr. e-mail til gf@computershare.dk.

Angivelse af den fuldmægtige skal være indsendt senest fredag den 23. april 2021 kl. 23.59, og brevstemmer skal være modtaget af selskabet eller Computershare A/S i overensstemmelse med ovenstående senest mandag den 26. april 2021 kl. 16.00.

Yderligere oplysninger

Frem til og med dagen for generalforsamlingen vil følgende yderligere oplysninger om generalforsamlingen være tilgængelige på Selskabets hjemmeside, www.virogates.com:

- Indkaldelse med dagsorden, fuldstændige forslag og bilag.
- De dokumenter, der skal fremlægges på generalforsamlingen, herunder årsrapporten for 2020
- Det samlede antal aktier og stemmerettigheder på datoen for indkaldelsen
- Fuldmagts- og brevstemmeblanket

UK

Due to the COVID-19 situation, the annual General Meeting is held as an electronic meeting without physical attendance.

The right to attend and vote at a general meeting may be exercised by shareholders who are registered in the share register on the record date or who have announced and documented their acquisition of shares for the purpose of registration in the share register by the record date. The record date is **Tuesday, April 20, 2021**.

A shareholder or a proxy may attend the annual general meeting together with an adviser.

Admission card

Admission cards for the Annual General Meeting may be requested no later than on Friday, April 23, 2021:

- online via the shareholder portal on the company's website, <https://www.virogates.com/shareholder-portal/>.
- by completing, signing and submitting the registration form by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26 D, first floor, 2800 Kgs. Lyngby, Denmark, or by using the registration form available on the company's website, <https://www.virogates.com/financial-calendar/>. Please note the delivery time of the postal services if the registration form is sent by ordinary mail; or
by contacting Computershare A/S, Lottenborgvej 26 D, first floor, 2800 Kgs. Lyngby, Denmark on tel. +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CEST).

Admission cards and details on how to participate in the electronic General Meeting will be sent to the email address specified in the shareholder portal upon registration. Links for download and information regarding requirements to systems will be shared with shareholders who have confirmed their participation.

For electronic participation, each shareholder is responsible for ensuring that the shareholder has a mobile phone or a desktop device with a web browser and that the shareholder has an adequate and functioning internet connection available at the time of the General Meeting.

Proxy and postal votes

You will be able to exercise your shareholder rights by issuing a proxy or by submitting a postal vote, but you cannot do both. The granting of proxy and postal voting can take place electronically via the shareholder portal available at <https://www.virogates.com/shareholder-portal/>. Login requires username and password or NemID. Proxy and postal voting can also take place using the forms available on the company's website, <https://www.virogates.com/financial-calendar/>. The completed form must be sent by ordinary mail to Computershare A/S, Lottenborgvej 26 D, first floor, DK-2800 Kgs. Lyngby, Denmark or by email to gf@computershare.dk.

Nomination of proxy must be received by the company or Computershare A/S in accordance with the above no later than Friday 23 April 2021 and postal votes must be received by the company or Computershare A/S in accordance with the above no later than Monday 26 April 2021 at 4:00 pm CEST.

Additional information

Until and including the day of the annual general meeting, additional information regarding the annual general meeting will be available on the Company's website, www.virogates.com:

- Notice to convene the annual general meeting with agenda, complete proposals and appendices.
- Documents to be presented at the annual general meeting, including the Annual Report 2020
- Information about the total number of shares and voting rights on the date of notice to convene
- Proxy and correspondence voting forms

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 700 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate

efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.